KIT and gastrointestinal stromal tumor: In contrast, IM-resistant GIST430 cells that acquired resistance to IM via KIT-driven mechanisms exhibited low sensitivity to the aforementioned FGFR and VEGFR inhibitors used alone or even in combination (Supplementary Figures S2 and S3), thereby indicating that combined anti-FGFR and VEGFR therapies might be highly effective for IM-resistant GIST-acquired resistance to IM via KIT-independent mechanisms.